Where is the safest place to start pharmaceutical manufacturing digitalisation?

Often a safer start is not a full electronic batch record, but one clear problem: deviation investigation data collection, equipment logs or a selected section of the batch record. The scope must be manageable and agreed in advance with the validation strategy.

How does an electronic batch record differ from a scanned PDF?

An electronic batch record controls data, sequence, permissible values, electronic signatures, audit history and exceptions. A scanned document merely replaces the medium, but does not create a controlled process.

Is MES essential for every pharmaceutical manufacturer?

Not always. The solution depends on product risk, batch volumes, existing systems and review costs. In some cases, LIMS, QMS, electronic logs or a deviation investigation platform create more value first.

How should data integrity be managed across multiple systems?

Clear primary data sources, synchronised time, immutable audit history, controlled access and documented data transfer are required. A report must not replace the primary record.

Where can AI be used without compromising quality accountability?

AI can help search for previous deviations, group signals and prepare source-based investigation material. The final cause, CAPA and batch release must remain the decisions of responsible specialists.

Which KPIs demonstrate the benefit of digitalisation?

Key indicators include batch review time, deviation investigation duration, number of record corrections, waiting time between manufacturing and release, proportion of repeated deviations and validation change cycle.

LT Let's Connect

Business area digitalisation analysis

Pharmaceutical and medical device manufacturing: digitalisation opportunities

Connecting planning, execution, quality, traceability and equipment data for medicines, biological products, medical devices and other regulated health products into a single managed manufacturing system.

Digital maturity Typical digital maturity Shows the level of digitalisation companies in this line of business typically operate at. The assessment considers use of core systems, how far processes are digitalised, integrations, data readiness and advanced use of data. A 3 means ordinary, middling maturity. A 5 is given only where real-time data, automated decisions and advanced optimisation are already a routine part of core operations.: medium
Digitalisation potential Digitalisation potential Shows the scale of business impact digitalisation could have in this line of business. It weighs economic leverage, the scope for digital impact, the scale and repetition of processes, value lost today, and the leverage of better data and decisions. A business area’s score is calculated from five weighted dimensions. A sector’s score is derived from the scores of its business areas.: 88/100
Biggest challenge: Quality control is separated from the production process
Biggest opportunity: Deviation and CAPA investigation data platform

Pharmaceutical and medical product manufacturing digitalisation should begin with a clear economic problem and one traceable data chain, rather than a general goal to 'implement MES' or collect as many equipment signals as possible.

How pharmaceutical and medical device manufacturing works

The business area covers the manufacture of pharmaceuticals, biological products, medical devices and other regulated healthcare products-from raw materials and component preparation to production, quality assurance, packaging, warehousing and dispatch.

The importance of product and process versioning

These data areas - approved formulas, master production records, material batches, methods, equipment, electronic signatures, deviations and validation evidence - must be managed as valid information, not freely copied files.

The link between physical and digital processes

Systems must reflect the actual state of facilities, including production lines, clean rooms, laboratory equipment, environmental monitoring and serialisation systems, as well as materials, operator actions and time.

The economics of exceptions

The greatest losses in pharmaceutical and medical device manufacturing arise from defects, rejects, failures, changes and quality waiting time, not from the ideal standard cycle.

The need for traceability and accountability

Solutions must be based on primary data and comply with GMP, data integrity, electronic records, validation and patient safety requirements.

Market and technology context

The FDA advanced manufacturing programme in 2025-2026 continues to support the deployment of innovative pharmaceutical manufacturing technologies; at the same time, risk-based quality management, model reliability and early regulatory dialogue are emphasised.

Product data and traceability pressureClients and oversight processes expect rapid provision of approved formulae, master batch records, material batches, methods, equipment, electronic signatures, deviations and validation evidence, and their linkage to actual production.
Skills shortageDigital instructions and decision history help retain material control, manufacturing, environmental and process monitoring, laboratory, release, packaging and serialisation knowledge within the organisation.
Raw material, energy and capacity costsManufacturing needs to see costs and losses at the level of product, batch and production line, clean room, laboratory equipment, environmental monitoring and serialisation system.
Advanced analytics maturityAI and forecasting become practical only when electronic batch record, laboratory results, deviations, CAPA and quality unit release decision are linked to reliable process context.

Typical value chain

Technology transfer and master data

Approved formulas, master records, methods, specifications, equipment and validation status.

Material and equipment readiness

Raw material release, equipment qualification, cleaning status and environmental conditions are verified.

Production execution is controlled

Operator actions, process parameters, electronic signatures and exceptions are recorded in an auditable environment.

Laboratory and deviations

Samples, results, unusual events and investigations are linked to a specific batch and process stage.

Batch review and release

The quality unit evaluates the complete record, deviations, CAPA and specification compliance.

Changes and continuous verification

Changes to process, system or method are managed through risk assessment, validation and monitoring KPIs.

Digital maturity pathway

Fragmented product and production data

Approved formulae, master batch records, material batches, methods, equipment, electronic signatures, deviations and validation evidence are kept in spreadsheets, documents and separate systems, and actual execution is verified after shift or batch.

Basic business systems

ERP manages orders and inventory, but material control, manufacturing, environmental and process monitoring, laboratory, release, packaging and serialisation and quality facts remain on paper or in local tools.

Digitalised selected process

On one line or product family, the single-product deviation investigation process or one portion of the electronic batch record is digitalised with clear validation boundaries, but integrations and common classifiers are still limited.

Integrated product and execution chain Typical current situation

Approved product and process information is linked to the plan, operator work, quality results and actual cost. Key managed areas: approved formulas, master batch records, material batches, methods, equipment, electronic signatures, deviations and validation evidence.

Data-driven manufacturing Target

Planning, quality and maintenance in pharmaceutical and medical device manufacturing rely on real-time exceptions, root cause analysis and reliable line and product KPIs.

Adaptive and closed-loop manufacturing

The system in pharmaceutical and medical device manufacturing automatically adjusts permissible solutions based on product, process and equipment status, whilst AI recommendations are audited and measured.

Key conclusion

Pharmaceutical and medical product manufacturing has very high digitalisation potential, but value is created not by yet another separate system, but by reliable connection between product version, plan, actual execution and quality.

Recommended starting point - a single product deviation investigation process or one part of an electronic batch record with clear validation boundaries. Such scope allows measuring results without involving all lines and integrations at once.

Most common digitalisation challenges

The largest gaps occur when master formulae, master production records, material batches, methods, equipment status, electronic signatures, deviations and validation evidence are managed in separate systems. Raw material control, production, environmental and process monitoring, laboratory, release, packaging and serialisation processes then fail to provide a single reliable actual history, meaning that plan, execution status and quality decisions reflect different situations.

Quality control is separated from the production process

Critical

Electronic batch record data, laboratory results, deviations, CAPA and release decisions are not consistently linked to a specific product or batch version, operation, equipment and cause of deviation.

Consequences: Quality decision-making takes longer, root cause is harder to establish, and batch review delays, repeated deviations, record corrections, additional investigations and validation change duration may recur in other orders.

Weak batch and component traceability

Critical

It is not always possible to quickly reconstruct the complete chain: formula, material batches, equipment, methods, electronic signatures, deviations and validation evidence.

Consequences: In pharmaceutical and medical device manufacturing, during a customer enquiry, audit, non-conformance or recall, it takes a long time to determine the affected scope and required action.

The electronic batch record is not seamless

Critical

Manufacturing, equipment, environmental, laboratory, materials and deviation records are collected in multiple validated and non-validated systems.

Consequences: Batch review is lengthy, data integrity risk is high and it is difficult to automate release.

Fragmented production master data

High

Master formulae, master production records, material batches, methods, equipment status, electronic signatures, deviations and validation evidence are stored in different systems, files or employee-prepared spreadsheets, meaning there is no single valid product and production version.

Consequences: Changes to raw material control, production, environmental and process monitoring, laboratory, release, packaging and serialisation processes arrive at different times, increasing manual checks and the risk of manufacturing based on outdated information.

Planning does not reflect actual production constraints

High

Plans do not always take into account validated equipment status, cleaning campaigns, material release, laboratory and qualified staff capacity and the actual status of work already started.

Consequences: Priorities are changed at the last minute, increasing waiting time, work in progress and the proportion of delayed orders in pharmaceutical and medical device manufacturing.

Production execution data is captured with a delay

High

In the process of investigating a deviation or electronic batch record for a selected product, operation start and finish, quantities produced, material consumption, stoppages and reasons for deviations are recorded with a delay or in multiple locations.

Consequences: Planners and responsible personnel see too late that the process of investigating a deviation or electronic batch record for a selected product has deviated from plan, losing time for correction.

Deviation investigations rely on manual data collection

High

The investigator manually collects process, equipment, laboratory, materials and previous event data.

Consequences: Investigations take a long time, root causes are determined inconsistently and batch release is delayed.

System and model validation is slow and document-intensive

High

Requirements, risks, tests, evidence, changes and periodic reviews are managed with a large volume of manual documentation.

Consequences: Technology deployment is slow and the cost of documenting changes is high.

Monitoring is mostly reactive

Medium

Data on production line, cleanroom, laboratory equipment, environmental monitoring and serialisation system uptime, failures, condition signals, spare parts and maintenance work is not aligned with actual load and production schedule.

Consequences: Unplanned stoppages disrupt the deviation investigation or electronic batch record process for the selected product, whilst maintenance and spare parts needs are managed on an urgent basis.

Opportunities

Greatest digitalisation opportunities

Deviation and CAPA investigation data platformVery high impactAutomatically collect related records, similar events and process context for the investigator.Faster and more consistent investigations

Electronic batch record and review by exceptionVery high impactConnect all critical batch data and automatically highlight only non-conformances and incomplete approvals.Faster release and data integrity

Digital validation lifecycleHigh impactLink requirements, risks, tests, evidence, changes and periodic reviews.Faster compliant technology deployment

Integrated quality and traceabilityVery high impactLink specification, batch, process parameters, checks, deviations and final product.Less waste and faster investigations

Integrated manufacturing execution managementVery high impactIn a selected flow, link formula, material batches, equipment, methods, electronic signatures, deviations and validation evidence with actual quantities, stoppages, deviation root causes and responsible worker actions.Performance and delivery reliability

Constraint-based planning and replanningVery high impactPlan according to actual capacities, changeovers, materials, tools, quality and deadlines.Capacity utilisation and shorter cycle

Data-driven equipment maintenanceHigh impactConnect failures, sensors, operating hours, spare parts and maintenance schedules.Less downtime

Energy, yield and waste optimisationHigh impactMeasure energy, material consumption and batch review waiting time, repeated deviations, record corrections, additional investigations and validation change duration at product, batch or serial unit level, so that the causes of losses are visible where they occur.Cost and sustainability

Biggest opportunity

Deviation and CAPA investigation data platform

The greatest near-term opportunity is a single-product deviation investigation process or one electronic batch record section with clear validation boundaries.

Higher utilisation of equipment and labour capacity
Less scrap and unplanned downtime
Shorter production cycle
Better traceability of batches and components

Potential business impact

Capacity utilisationA more accurate plan and real-time execution status of validated equipment condition, cleaning campaigns, material release, laboratory and qualified staff capacity reduces waiting and urgent priority changes.
Quality and yieldQuality status becomes visible during the process as the following data and decisions are linked: electronic batch record, laboratory results, deviations, CAPA and quality unit release decision. This reduces late scrap, rework and raw material losses.
Delivery reliabilityOrder deadline is assessed based on actual raw material control, production, environmental and process monitoring, laboratory, release, packaging and serialisation and material status, rather than periodic reporting.
Traceability and riskA reliable chain between approved formula, master batch records, material batches, methods, equipment, electronic signatures, deviations and validation evidence enables faster response to audit, complaint or recall scenarios.
Scale and knowledge preservationDigital instructions and decision history in pharmaceutical and medical device manufacturing reduce dependency on individual specialists' memory.

Sprendimai

How to solve these problems

Solution directions linked to specific business area problems they address.

Problem

Manufacturing execution data collected late

Solution direction

Manufacturing execution system (MES)

Manages raw material control, production, environmental and process monitoring, laboratory, release, packaging and serialisation tasks, validated product version, actual quantities, time, materials, stoppages and exceptions in one selected flow.

Problem

Planning does not reflect actual production constraints

Priorities are changed at the last minute, increasing waiting time, work in progress and the proportion of delayed orders in pharmaceutical and medical device manufacturing.

Solution direction

Manufacturing execution system (MES)

Problem

Planning does not reflect actual production constraints

Priorities are changed at the last minute, increasing waiting time, work in progress and the proportion of delayed orders in pharmaceutical and medical device manufacturing.

Solution direction

Advanced planning and scheduling system

Creates and adjusts the plan according to validated equipment status, cleaning campaigns, material release, laboratory and qualified employee capacity, actual material status and current production exceptions.

Problem

Quality control separated from production process

Solution direction

Quality and traceability platform

Links electronic batch record, laboratory results, deviations, CAPA and quality unit release decision to approved product version, actual materials, operations, equipment and final product.

Problem

Weak batch and component traceability

In pharmaceutical and medical device manufacturing, during a customer enquiry, audit, non-conformance or recall, it takes a long time to determine the affected scope and required action.

Solution direction

Quality and traceability platform

Links electronic batch record, laboratory results, deviations, CAPA and quality unit release decision to approved product version, actual materials, operations, equipment and final product.

Problem

Maintenance mostly reactive

Solution direction

Equipment maintenance and reliability system

Manages equipment register covering production line, clean room, laboratory equipment, environmental monitoring and serialisation systems, planned maintenance, failures, spare parts and status signals with production context.

When it is worth starting

Investment justified

The data set in these areas - approved formulae, master batch records, material batches, methods, equipment, electronic signatures, deviations and validation evidence - has multiple versions or is frequently corrected manually
Raw material control, production, environmental and process monitoring, laboratory, release, packaging and serialisation facts are recorded after the shift or batch
For a quality investigation, it is difficult to link the electronic batch record, laboratory results, deviations, CAPA and quality unit release decision to a specific batch, product or equipment
The costs of scrap, downtime, waiting or non-traceability in pharmaceutical and medical device manufacturing are significant
A clear scenario can be selected: a deviation investigation process for a single product or a portion of the electronic batch record with clear validation boundaries

Proceed with care

It is unclear which problem has the greatest business impact
There are no approved product and process versions
Equipment data is collected without product or batch context
The first version is planned for the entire factory at once

Recommended first version

The first version is a single product deviation investigation process or one part of an electronic batch record with clear validation boundaries. It must include approved master data, one real execution flow, a quality decision and a measurable economic result.

Approved work order and product version

The user receives only valid approved formulae, master production records, material batches, methods, equipment, electronic signatures, deviations and validation evidence, and a clear operation and quality task.

Actual execution recording

Quantities, time, materials used, raw material control, production, environmental and process monitoring, laboratory, release, packaging and serialisation status, stoppages and exceptions are recorded.

Integrated quality and traceability control

Quality data and decisions-electronic batch record, laboratory results, deviations, CAPA and quality unit release decision-are linked to product, batch, equipment and operation.

Exceptions and results dashboard

Managers see not a general report, but delayed, missing or risky single product deviation investigation process or one part of an electronic batch record with clear validation boundaries statuses.

Who to start withProduction operators or process executors · Shift or production managers · Planners and technologists · Quality specialists · Maintenance or engineering team
What not to include in the first versionEntire factory and all products scope · Full integration of all legacy equipment · Complex autonomous AI optimisation · Historical data cleaning without a clear use scenario

Investment priorities

Data platform for deviations and CAPA investigationsStart with a single product deviation investigation process or one part of the electronic batch record with clear validation boundaries and measure the economic result before scaling up.
Electronic batch record and review by exceptionConnect quality information - electronic batch record, laboratory results, deviations, CAPA and quality unit release decision - with the actual product, batch and process history.
Digital validation lifecycleOnly after stabilising the first flow, expand planning, production line, cleanroom, laboratory equipment, environmental monitoring and serialisation system integrations and advanced analytics.

Key implementation conditions

Clear primary data system

There must be agreement on which system stores the valid information in areas such as approved formulas, master production records, material batches, methods, equipment, electronic signatures, deviations and validation evidence, and how changes reach production.

IT and production automation boundaries

Production lines, clean rooms, laboratory equipment, environmental monitoring and serialisation systems integration must be designed without compromising the security of control networks, equipment warranties and production continuity.

Contextual actual data

Every measurement or operator action in pharmaceutical and medical products manufacturing must be linked to product, batch, operation, facility and time; a signal archive alone creates no value.

Workstation, not an additional report

The operator or specialist must receive only the information required for their decision, and recording must be incorporated into the raw material control, production, environmental and process monitoring, laboratory, release, packaging and serialisation workflow.

Managed change and accountability

Process owners must approve decisions concerning versions, exceptions and GMP, data integrity, electronic records, validation and patient safety requirements; the technology team cannot define business rules alone.

Recommended implementation sequence

Economic challenges and boundary selection

Select a single product deviation investigation process or a clearly bounded part of the electronic batch record and agree on which loss and KPIs the first version should impact.

Master data and identifier preparation

Organise approved formulae, master production records, material batches, methods, equipment states, electronic signatures, deviations and validation evidence, and define uniform product, batch or serial number, operation and equipment identifiers.

One seamless digital process

Implement a single product deviation investigation process or a clearly bounded part of the electronic batch record from approved initial information to actual result, quality decision and audit history.

Usage stabilisation

Launch the solution in the selected product deviation investigation or electronic batch record process, eliminate parallel records and verify data and KPI reliability.

Expansion and advanced analytics

Only after stable use expand the solution to other product groups, batch records and laboratory processes and connect more advanced analytics or AI scenarios.

Change measurement KPIs

Manufacturing plan execution on time% of orders or operations

Measure what proportion of planned orders or operations are executed on time when the plan accounts for validated equipment status, cleaning campaigns, material release, laboratory and qualified staff capacity.

First-time-right production proportion% of units or batches

Measure the proportion of production for which electronic batch record data, laboratory results, deviations, CAPA and release decisions are confirmed without correction, rework or additional investigation.

Unplanned downtime durationhrs

Assess the reliability of critical production lines, clean rooms, laboratory equipment, environmental monitoring and serialisation systems and the outcome of response to unplanned stoppage.

Proportion of fully traceable batches or units% of production

Measure whether formula, material batches, equipment, methods, electronic signatures, deviations and validation evidence are linked in a single reliable history.

Manufacturing cycle timehrs or days

Measure the time from production start to finished and quality-released product for a selected product's deviation investigation or electronic batch record process.

Actual and planned cost variance% or € per unit

Assess whether actual labour time, materials, scrap, energy and other direct costs are reliably attributed to formula, material batches, equipment, methods, electronic signatures, deviations and validation evidence.

Deviation investigation and batch review durationdays

Measure the time from deviation registration to completion of confirmed root cause, CAPA and batch review.

Key risks

Digitalising an undefined processIf the rules and exceptions applicable to raw material control, production, environmental and process monitoring, laboratory, release, packaging and serialisation processes are unclear, the system will only cement different employee practices.How to manage Before development, observe actual work, describe the most common exceptions and confirm decision rights.
Product and production versions do not matchApproved formulae, batch records, material batches, methods, equipment statuses, electronic signatures, deviations and validation evidence can be changed at different times, so production risks receiving invalid or mutually inconsistent information.How to manage Pharmaceutical and medical device manufacturing use identical identifiers, effective dates and approval statuses; an unapproved version must not be transferred to production.
Equipment data collected without contextA high volume of signals from production lines, cleanrooms, laboratory equipment, environmental monitoring and serialisation systems does not help explain the outcome if the data are not linked to the product, batch or serial number, operation and specific time.How to manage Assign in advance to data from production lines, cleanrooms, laboratory equipment, environmental monitoring and serialisation systems a specific solution, KPI, responsible person and product, batch or serial number context.
First version covers too muchAn attempt to immediately cover all lines, products and GMP, data integrity, electronic records, validation and patient safety scenarios delays actual use and makes it difficult to evaluate the outcome.How to manage Limit the first version to one product deviation investigation process or a clearly bounded part of the electronic batch record.
Users bypass the systemIf the new workplace slows down raw material control, production, environmental and process monitoring, laboratory, release, packaging and serialisation processes or does not help resolve exceptions, employees will continue to fill in paper or spreadsheets after the fact.How to manage Design the workplace together with production, quality assurance, laboratory, validation, engineering and IT teams, measure registration time and remove duplicate forms only after stable go-live.

Shorten deviation investigation without losing control

An assessment should be made of whether it is best to begin the first stage with a deviation investigation process for a single product or a clearly bounded section of the electronic batch record, and what change in quality, time, cost or traceability can be reliably measured.

Discuss the digitalisation direction

Pharmaceutical and medical device manufacturing: digitalisation opportunities

How pharmaceutical and medical device manufacturing works

The importance of product and process versioning

The link between physical and digital processes

The economics of exceptions

The need for traceability and accountability

Market and technology context

Typical value chain

Technology transfer and master data

Material and equipment readiness

Production execution is controlled

Laboratory and deviations

Batch review and release

Changes and continuous verification

Digital maturity pathway

Fragmented product and production data

Basic business systems

Digitalised selected process

Integrated product and execution chain Typical current situation

Data-driven manufacturing Target

Adaptive and closed-loop manufacturing

Key conclusion

Related digitalisation topics

Most common digitalisation challenges

Quality control is separated from the production process

Weak batch and component traceability

The electronic batch record is not seamless

Fragmented production master data

Planning does not reflect actual production constraints

Production execution data is captured with a delay

Deviation investigations rely on manual data collection

System and model validation is slow and document-intensive

Monitoring is mostly reactive

Greatest digitalisation opportunities

Deviation and CAPA investigation data platform

Potential business impact

How to solve these problems

Recommended digital solutions

Manufacturing execution system (MES)

Advanced planning and scheduling system

Quality and traceability platform

Equipment maintenance and reliability system

Production master data and change management

Electronic batch record and review platform

Deviation, CAPA and quality events management system

Digital computerised systems validation platform

When it is worth starting

Recommended first version

Approved work order and product version

Actual execution recording

Integrated quality and traceability control

Exceptions and results dashboard

Investment priorities

Key implementation conditions

Clear primary data system

IT and production automation boundaries

Contextual actual data

Workstation, not an additional report

Managed change and accountability

Recommended implementation sequence

Economic challenges and boundary selection

Master data and identifier preparation

One seamless digital process

Usage stabilisation

Expansion and advanced analytics

Change measurement KPIs

Key risks

Digital innovation in the business area

Exception-based batch review

Source-based deviation investigation assistant

Advanced process analytics

Digital validation evidence management

Frequently asked questions

Where is the safest place to start pharmaceutical manufacturing digitalisation?

How does an electronic batch record differ from a scanned PDF?

Is MES essential for every pharmaceutical manufacturer?

How should data integrity be managed across multiple systems?

Where can AI be used without compromising quality accountability?

Which KPIs demonstrate the benefit of digitalisation?

Shorten deviation investigation without losing control